HALO

NASDAQ · Biotechnology

Halozyme Therapeutics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$62.04

-0.82 (-1.30%)

As of Mar 24, 9:46 PM ET ·

Analyst Consensus

Buy

Analysts

High

Coverage

Buy 11 73%

Hold 3 20%

Sell 1 7%

Price Target

Analyst Price Target -66.1% upside

Low Target $15.29

Average Target $21.02

High Target $24.22

Current Price $62.04

Current
$62.04

Target
$21.02

$15.29 $21.02 avg $24.22

Scenario Analysis

Bear Case

$15.29

-75.4%

Low target

Base Case

$21.02

-66.1%

Avg target

Bull Case

$24.22

+-61.0%

High target

Risk/Reward

0.8x

Unfavorable

Price in Context

52-Week High

$82.22

-24.5% from high

52-Week Low

$47.50

+30.6% from low

50-Day SMA

$71.23

-12.9% vs SMA

200-Day SMA

$65.75

-5.6% vs SMA

RSI (14)

47.6

Neutral

Target vs 52W High

$21.02

-74.4% vs high

Peer Consensus — Biotechnology

Stock	Consensus	Analysts	Buy %	Target	Upside
ABBV Abbvie Inc	Buy	39	69%	$257.58	+25.5%
AMGN Amgen Inc	Hold	42	50%	$190.87	-45.2%
GILD Gilead Sciences Inc	Strong Buy	37	81%	$362.68	+162.6%
VRTX Vertex Pharmaceuticals Inc	Strong Buy	39	79%	$438.34	-2.3%
REGN Regeneron Pharmaceuticals	Strong Buy	36	75%	$76.80	-89.6%
ALNY Alnylam Pharmaceuticals Inc	Strong Buy	36	78%	$102.31	-66.8%
INSM Insmed Inc	Strong Buy	26	92%	$143.40	+3.1%
NTRA Natera Inc	Strong Buy	27	89%	$142.91	-26.5%